Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Apollomics Inc. - Class A Ordinary Shares (NQ: APLM )

6.800 +0.580 (+9.32%)
Streaming Delayed Price Updated: 12:43 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apollomics Inc. - Class A Ordinary Shares

< Previous 1 2 3 4 5 Next >
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress
From Apollomics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib
From Apollomics Inc.
Via GlobeNewswire
(APLM) - Analyzing Apollomics's Short Interest
Via Benzinga
What's Going On With Apollomics (APLM) Stock Exploding Higher?
Via Benzinga
Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
From Apollomics Inc.
Via GlobeNewswire
Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split
The Company's class A ordinary shares will begin trading on a split-adjusted basis on November 25, 2024 
From Apollomics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Dow Dips Over 300 Points; Walmart Raises FY25 Forecast
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Tesla Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Dow Falls 100 Points; Brady Posts Upbeat Results
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024
Vebreltinib is efficacious in both treatment naïve and previously treated patients with NSCLC with METex14 skipping, and regardless of co-occurring MET amplification 
From Apollomics Inc.
Via GlobeNewswire
Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Apollomics Inc.
Via GlobeNewswire
Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress
From Apollomics Inc.
Via GlobeNewswire
S&P 500 Gains 1%; Home Depot Earnings Top Views
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Penny Stock Apollomics Trading Higher On Tuesday?
Apollomics shares soared after revealing promising Phase 2 SPARTA trial data for vebreltinib in non-CNS MET fusion solid tumors, showing a 43% ORR with notable responses in metastatic NSCLC,... 
Via Benzinga
Nasdaq Surges 200 Points; US Producer Prices Increase 0.1% In July
Via Benzinga
Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial
43% overall response rate: Six confirmed responses (including one complete response in metastatic non-small cell lung cancer and five partial responses) confirmed by RECIST 1.1 out of 14 patients with... 
From Apollomics Inc.
Via GlobeNewswire
Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference
From Apollomics Inc.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are worth diving into this morning and we have all of the hottest news worth checking out on Thursday! 
Via InvestorPlace
Why Chuy's Holdings Shares Are Trading Higher By 47%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement
From Apollomics Inc.
Via GlobeNewswire
Apollomics Announces Updated Strategic Focus and Leadership Team Changes
Focus on vebreltinib study enrollment for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations targets greatest unmet medical need 
From Apollomics Inc.
Via GlobeNewswire
Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Data from Phase 2 and 2/3 trials demonstrate continued efficacy and safety of vebreltinib for treating different tumor types carrying MET-driver alterations 
From Apollomics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Apollomics Announces Presentation at the 2024 BIO International Convention
From Apollomics Inc.
Via GlobeNewswire
Apollomics Announces Private Placement Financing and Addition to Board of Directors
From Apollomics Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.